Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bactiguard Holding ABCHIX:BACTBS 60 3-Year EPS without NRI Growth Rate is 47.70% as of Jun. 2026, which is at its 10-year median of 47.70. GuruFocus rates CHIX:BACTBS with a GF Score™ of 60/100 and a GF Value™ of kr240.32. The stock has 2 warning signs investors should review. Among 662 Medical Devices & Instruments companies, Bactiguard Holding AB ranks better than 87.92% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 47.70% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 20.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Bactiguard Holding AB was 94.10% per year. The lowest was -102.60% per year. And the median was 47.70% per year.
Bactiguard Holding AB (CHIX:BACTBs) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Bactiguard Holding AB 3-Year EPS without NRI Growth Rate Related Terms
CHIX:BACTBS vs ABT, SYK, MDT: 3-Year EPS without NRI Growth Rate Comparison
For the Medical Devices subindustry, Bactiguard Holding AB's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bactiguard Holding AB 3-Year EPS without NRI Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bactiguard Holding AB's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Bactiguard Holding AB's 3-Year EPS without NRI Growth Rate falls into.
Bactiguard Holding AB 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 47.70% mean?
Bactiguard Holding AB (CHIX:BACTBS) has a 3-Year EPS without NRI Growth Rate of 47.70% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Bactiguard Holding AB and its competitors. This is near median its historical median of 47.70. According to the industry distribution chart, Bactiguard Holding AB ranks #80 out of 662 companies in the Medical Devices & Instruments industry, placing it in the top 12.1%.
Is Bactiguard Holding AB's 3-Year EPS without NRI Growth Rate too high?
Bactiguard Holding AB's current 3-Year EPS without NRI Growth Rate of 47.70% is near median its 10-year median of 47.70. The Medical Devices & Instruments industry median 3-Year EPS without NRI Growth Rate is 7.90. Bactiguard Holding AB's value of 47.70% is 503.8% above this industry median. Based on the distribution chart, Bactiguard Holding AB ranks #80 out of 662 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Bactiguard Holding AB has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Bactiguard Holding AB's 3-Year EPS without NRI Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Bactiguard Holding AB ranks #80 out of 662 companies for 3-Year EPS without NRI Growth Rate. This places Bactiguard Holding AB in the top 12% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 7.90. Bactiguard Holding AB's value of 47.70% is 503.8% above this benchmark. While the company's 10-year median is 47.70 vs. the industry median of 7.90, Bactiguard Holding AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EPS without NRI Growth Rate among Medical Devices & Instruments companies is 7.90, based on 662 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bactiguard Holding AB's current 3-Year EPS without NRI Growth Rate of 47.70% is 503.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Bactiguard Holding AB and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EPS without NRI Growth Rate is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bactiguard Holding AB's current 3-Year EPS without NRI Growth Rate is 47.70%, which is near median its own 10-year median of 47.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bactiguard Holding AB stock overvalued right now?
Bactiguard Holding AB (CHIX:BACTBS) has a current 3-Year EPS without NRI Growth Rate of 47.70%. The stock's GF Value™ is kr240.32, compared to a current price of kr128.60 — trading 46.5% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 47.70%, which is near median its 10-year median of 47.70 and 503.8% above the Medical Devices & Instruments industry median of 7.90. Bactiguard Holding AB's overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Bactiguard Holding AB (CHIX:BACTBS), the current 3-Year EPS without NRI Growth Rate is 47.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bactiguard Holding AB (CHIX:BACTBS) Overvalued in 2026?
Based on GuruFocus' analysis, Bactiguard Holding AB stock appears to be undervalued.
The current stock price of kr128.60 is trading 46.5% below its estimated GF Value™ of kr240.32.
Key valuation signals for CHIX:BACTBS:
3-Year EPS without NRI Growth Rate: 47.70% (near median its 10-year median of 47.70)
GF Value™: kr240.32 vs. price of kr128.60 (46.5% below fair value)
Industry Position: 503.8% above the Medical Devices & Instruments median (#80 of 662)
No single metric tells the full story. See the CHIX:BACTBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bactiguard Holding AB is a medical device company. It is engaged in a MedTech company developing safe and biocompatible technology to prevent medical device-related infections. The technology is based on an ultra-thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices. The company focuses on five strategic therapeutic areas wherein infection rates create high medical needs for infection prevention. These areas include Orthopedics, Cardiology, Neurology, Urology, and Vascular Access. Geographically, the company operates in the USA, Malaysia, China, Saudi Arabia, Bangladesh, Sweden, the Czech Republic, and Other countries. The majority of its revenue is generated from the USA region.
60GF Score
Get the complete analysis for CHIX:BACTBS
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BACTBS has been successfully added to your 
